Arthur Klausner, Chief Executive Officer
Gerald M. Walsh, Ph.D., President and COO
Richard D. Olson, Ph.D., Chief Science Officer
Gem Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary anthracycline derivatives specifically designed to eliminate the critical cardiotoxicity side effect of this powerful class of chemotherapeutics while maintaining their well-documented anti-cancer efficacy. In so doing, Gem effectively transforms traditional broad-spectrum cytotoxic drugs into modern – and biochemically targeted – anti-cancer agents that hold the potential for higher dosing and correspondingly improved therapeutic utility.
Hendricks Holding Co. is a significant investor in Gem.